| DRUG WATCH |
|
| Year : 2010 | Volume
: 42
| Issue : 5 | Page : 320-321 |
Sitagliptin-induced hemolysis
Ragini Bekur, MV Nagaraja, KN Shivashankara, Weena Stanley
Department of Medicine, Kasturba Medical College, Manipal University, Manipal, India
Correspondence Address:
Ragini Bekur
Department of Medicine, Kasturba Medical College, Manipal University, Manipal
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0253-7613.70405
Sitagliptin is a newer oral hypoglycemic drug of the dipeptidyl peptidase-IV inhibitor class. It appears to be a promising newer oral hypoglycemic agent. The advantages are the absence of hypoglycemia when used as monotherapy and they cause less gain weight. We report a case of sitagliptin-induced hemolysis, a rare side effect, not reported in the literature. As sitagliptin is widely used in type 2 diabetes mellitus physicians should be aware of the possibility of this rare but potentially serious adverse drug reaction.
[FULL TEXT] [PDF]*
|
